# Dabigatran

## Pradaxa 150mg

##### 臨採

| 藥品代碼   | OPR150                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 用法用量   | Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation: adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily， with or without food. For prophylaxis of venous thrombosis of hip replacement surgery， starting 75mg within 1-4 hours after the operation， then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days， then 150mg twice a day for 6 months. |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 腎功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 禁忌       | Pathological bleeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 副作用     | Gastrointestinal: Dyspepsia (11%; includes abdominal discomfort/pain， epigastric discomfort) GI hemorrhage (<6%)， gastritis-like symptom Hematologic: Bleeding (8% to 33%; major: <6%) Anemia (1% to 4%) hematoma (1% to 2%) hemoglobin decreased (1% to 2%) hemorrhage (postprocedural or wound: 1% to 2%) Hepatic: ALT increased (>3 x ULN: 2% to 3%) Renal: Hematuria (1%) Miscellaneous: Wound secretion (5%)， postprocedural discharge (1%)                                                                                                                                                          |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Pradaxa 110mg

##### 

| 藥品代碼   | OPRAD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Prevention of venous thromboembolic events in patients who have undergone elective total hip or knee replacement surgery; stroke & systemic embolism in patients w/ atrial fibrillation in whom anti-coagulation is appropriate.                                                                                                                                                                                                                                                                                                                                                                            |
| 用法用量   | Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation:adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily， with or without food. For prophylaxis of venous thrombosis of hip replacement surgery， starting 75mg within 1-4 hours after the operation， then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days， then 150mg twice a day for 6 months. |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 腎功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 禁忌       | Severe renal impairment (CrCl <30 mL/min)， haemorrhagic manifestations， bleeding diathesis or patients w/ spontaneous or pharmacological impairment of haemostasis， lesions at risk of clinically significant bleeding， concomitant treatment w/ strong p-glycoprotein (p-gp) inhibitors eg ketoconazole.                                                                                                                                                                                                                                                                                               |
| 副作用     | Anemia， GI haemorrhage， haematoma， hematuria， wound haemorrhage; wound secretion， postprocedural haematoma， postprocedural haemorrhage， post-op anemia， traumatic haematoma， postprocedural discharge; ALT ≧3 x ULN， decreased haemoglobin. Epistaxis， urogenital haemorrhage; abdominal pain， diarrhoea， dyspepsia， nausea.                                                                                                                                                                                                                                                                  |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

